The transcriptional regulator ecotropic viral integration site-1 (EVI-1) has mainly been studied for its role in myeloid malignancies, in which high EVI-1 levels are associated with particularly aggressive disease. The role of EVI-1 in lymphoid cells, however, is largely unknown. Here we show that EVI-1 is indeed expressed in lymphoid malignancies such as acute lymphoblastic leukemia (ALL) and a subset of chronic lymphocytic leukemia. Expression data from pediatric ALL further suggest that high EVI-1 levels are associated with poor prognosis. Suppression of EVI-1 expression by RNA interference reduces cell growth and enhances apoptosis sensitivity in response to various stimuli in lymphoblastic leukemia cells. At the molecular level, EVI-1 modulates expression of several apoptosis-related genes (such as BCL2, BCL-x, XIAP, NOXA, PUMA, TRAIL-R1). Furthermore, EVI-1 knockdown strongly impairs in vivo engraftment of lymphoblastic leukemia cells upon transplantation in immune-permissive NOD/SCID/IL2Rg null mice, conferring a survival benefit when compared with mice transplanted with control cells. Thus, our data show that EVI-1 is expressed not only in myeloid but also in lymphoid leukemias, and contributes to the leukemogenic potential and apoptosis resistance of ALL cells.
INTRODUCTION
The ecotropic viral integration site-1 gene (EVI-1) was identified more than 20 years ago as a common locus of retroviral integration in murine myeloid tumors. 1 Since then, EVI-1 has evolved as one of the most potent oncogenes associated with myeloid malignancies, such as acute myeloid leukemia (AML), chronic myeloid leukemia (CML), juvenile myelomonocytic leukemia and myelodysplastic syndrome (MDS). 2, 3 In mouse models, adult animals develop MDS upon activation of the EVI-1 gene in the bone marrow (BM), 4 whereas additional events, such as Hox and Meis activation are required for development of overt leukemia. 5 High expression of the EVI-1 gene is found in approximately 10% of human AML, correlating with a poor clinical outcome. 6, 7 In CML, induction of EVI-1 expression occurs during blast crisis, but is also detectable in approximately 10% of imatinib-resistant chronic phase CML patients displaying unfavorable prognosis. 8 The human EVI-1 gene is located on chromosome 3q26, and EVI-1 induction in AML and MDS has been partly associated with rearrangements of this chromosomal locus. 2, 3 Aberrant EVI-1 expression, however, also occurs in disease lacking 3q26 abnormalities. 6, 9 Beside its role in myeloid malignancies, EVI-1 has important roles during embryonic development where it can be detected in several organs such as brain, kidney, intestine and lung. 10, 11 Murine knockout embryos display hypocellularity and broad defects, and die early during embryonic development due to hemorrhaging and heart failure. 12, 13 In murine hematopoietic stem cells (HSC), targeted deletion of EVI-1 causes proliferation defects that can be rescued by the EVI-1 target gene Gata2. 13 Whereas data on the role of EVI-1 in human development are not available, expression analyses in human CD34
þ cells suggest a role in human HSC biology. [14] [15] [16] Molecularly, EVI-1 is a member of the SET/PR domain family of zinc finger transcription factors that are organized in two discrete domains, each of them with distinct DNA-binding specificities. 17, 18 EVI-1 generates transcriptional complexes by recruiting different proteins, such as Smad3 or the co-repressor CtBP. 19, 20 More recently, interaction with histone deacetylases and methyltransferases have also been reported. [21] [22] [23] [24] Despite intense studies on EVI-1 in myeloid disorders, information on its expression and role in lymphoid neoplasia remains scarce. A sporadic occurrence of balanced 3q26 aberrations has been previously detected in lymphoid neoplasms and EVI-1 rearrangement was reported in a T-cell non-Hodgkin lymphoma patient carrying a t(3;9)(q26;p23) translocation. 25 In a follow-up study, however, De Weer et al. 26 could not detect EVI-1 mRNA expression in a limited number of samples of adult T-cell acute lymphoblastic leukemia (T-ALL).
Given the oncogenic potential of EVI-1 for myeloid malignancies and the lack of information on the role of EVI-1 in lymphoid neoplasms, we performed a detailed expression analysis. Our retrospective analysis of microarray data deposited in the Oncomine database revealed EVI-1 expression in a series of adult and pediatric ALL.
B-cell-derived ALL. To explore the functional relevance of EVI-1 expression in ALL, we established a stable EVI-1 knockdown in selected ALL cell lines. Indeed, inhibition of EVI-1 expression reduced cell growth and conferred increased apoptosis sensitivity in response to various pro-apoptotic stimuli. Expression of genes involved in both the intrinsic and extrinsic apoptosis pathways was modulated by EVI-1. Importantly, inhibition of EVI-1 expression reduced the leukemogenic capacity of ALL cells upon xenotransplantation in immunopermissive NOD/SCID/IL2Rg null mice and conferred a survival benefit. Thus, our data suggest that EVI-1 is expressed in lymphoid malignancies and contributes to the leukemogenic potential and apoptosis resistance of ALL cells.
MATERIALS AND METHODS

Human samples and cell lines
Following approval by the Ethics Review Board of the University of Tuebingen, primary samples enriched for mononuclear cells were collected before onset of treatment from BM or peripheral blood (PB) of patients presenting with high numbers of blasts, as described. 30 Primary samples were derived from pediatric c-ALL (n ¼ 23, 22 BM, 1 PB), pediatric T-ALL (n ¼ 10, 8 PB, 2 BM), adult ALL (n ¼ 3, PB), adult CLL (n ¼ 18, PB), adult AML (n ¼ 21, BM) and healthy individuals (n ¼ 5, BM). The pediatric ALL high-risk patient group was defined by two criteria: First, we considered patients that died within 3 years from progressive leukemia as high risk. In addition, pediatric patients with insufficient response to cytoreductive therapy according to the German ALL-BFM 2000 protocol were included (defined either by poor response 7 days after induction of therapy with prednisone or by morphological non-response at day 33 of therapy (middle of induction therapy, minimal residual disease time point 1) or by positive minimal residual disease levels defined as 410 À 3 leukemic cells within the BM mononuclear cells at day 78 of therapy (regeneration after induction therapy, minimal residual disease time point 2)). All other patients were considered as non-high-risk. 31 NALM-16 cells (pediatric precursor B-ALL line) were kindly provided by HJ Bü hring (University of Tuebingen). REH, Daudi, SC-1, CML-T1, Jurkat and SK-OV3 cells were purchased from ATCC (Wesel, Germany) or DSMZ (Braunschweig, Germany). Cell lines were grown in RPMI-1640 supplemented with 10% fetal calf serum and 1% Pen/Strep (PAA, Pasching, Austria). To monitor growth, cells were seeded in 48-well plates (2.5 Â 10 4 cells in 250 ml medium/well) and counted on days 3, 6 and 9.
Gene expression analysis RNA isolation and cDNA preparation were performed as described. 30 EVI-1 gene transcripts were detected by quantitative real-time reversetranscription PCR (qRT-PCR) using a LightCycler 480 instrument and LightCycler probes master mix (Roche, Mannheim, Germany). Primer sequences are listed in Supplementary Table 1 . Sequencing of the 96-bp fragment confirmed amplification of human EVI-1. Mean C t of EVI-1 in the BM samples of five healthy patients was used as calibrator. Relative expression was determined by using the DDC t method, and high EVI-1 expression was defined as expression higher than the cutoff value 25 relative to healthy BM as previously described. 6 To prevent bias, the survival analysis was also performed at cutoff points of 10, 50 and 100, as described. 6 Transcripts of anti-apoptotic (XIAP, BCL2, p21, BCL-x, MCL1, BCL2L1A1) and pro-apoptotic genes (PUMA, NOXA, BID, BIK, BAK1, BAX), as well as of TRAIL-R1 and TRAIL-R2 were detected by qRT-PCR using SYBR Green Assay (Eurogentec, Cologne, Germany) and QuantiTect Primer Assay (Qiagen, Hilden, Germany). Relative expression levels were calculated after normalization to the reference gene PBGD.
Lentiviral transduction
Lentiviruses carrying EVI-1 small hairpin RNA (shRNA) or control constructs were designed using the MISSION TRC shRNA platform and the vector pLKO.1-Puro (Sigma-Aldrich, St Louis, MO, USA) or as described. 32 Overexpression and control vectors were kindly provided by Olga Kustikova and Christopher Baum (Hannover Medical School, Hannover, Germany). 33 Detailed information on constructs and transduction procedure is presented in the Supplementary Material. siRNA treatment Silencer Select small interfering RNAs (siRNAs) for tumor necrosis factorrelated apoptosis-inducing ligand (TRAIL)-R1 and TRAIL-R2 were purchased from Invitrogen (Carlsbad, CA, USA). Transfection was performed using Lipofectamine RNAiMAX reagent (Invitrogen). Seventy-two hours after transfection, knockdown efficiency was tested by qRT-PCR analysis.
Immunofluorescence and immunoblot analysis
Immunocytochemical staining was performed as described. 30 In brief, cells were fixed in 4% para-formaldehyde in phosphate-buffered saline and permeabilized in ice-cold methanol. EVI-1 rabbit mAb (C50E12, Cell Signaling Technology, Danvers, MA, USA) was added at a 1:400 dilution and Alexa Fluor 488 goat anti-rabbit antibody (Invitrogen) used as secondary antibody. APC anti-human CD261 (TRAILR1) was purchased from Biolegend (San Diego, CA, USA); CD45(HI30)-PECy7, CD33(SHCL-1)-FITC, CD34(8G12)-PerCP, CD19(SJ25C1)-APC, CD20(L27)-PE were purchased from BD Pharmingen (Heidelberg, Germany); CD10(SS2/36)-PE, IgGk(F0434)-FITC, IgGl(R0437)-PE and IgGl(F0437)-FITC were purchased from Dako (Glostrup, Denmark); and CD10(MEM-78)-PerCP was purchased from ExBio Praha (Vestec, Czech Republic). Flow cytometric analysis was performed on a FACSCanto II using FACSDiva software (BD Biosciences, Franklin Lakes, NJ, USA). Immunoblot analysis was performed using EVI-1 rabbit mAb (1:5000) and anti-mouse b-actin (Li-COR Biosciences, Lincoln, NE, USA; 1:5000) antibodies. For the detection of active caspase-3 and poly (ADP-ribose) polymerase (PARP) cleavage, we used cleaved caspase-3 (Asp175) and PARP antibodies from Cell Signaling Technology. Detection was performed using IRDye 800CW-conjugated goat anti-rabbit IgG and IRDye 680 anti-mouse IgG antibodies (Li-COR Biosciences; 1:5000), and scanning of the membranes on an Odyssey Imager (Li-COR Biosciences). Quantification of western blots was also performed using an Odyssey Imager, and ratios in relation to the b-actin loading control were calculated.
Cell cycle analysis and detection of apoptosis Cells were seeded at 1 Â 10 6 cells/ml, and after 6 days of incubation, fixed in 70% ice-cold ethanol to perform cell cycle analysis using propidium iodide (PI). Apoptotic cells were determined by PI staining to detect subdiploid DNA 34 or with the Annexin V-APC/7-AAD kit (BD Pharmingen). Caspase-3/7 activities were assayed using the Caspase-Glo 3/7 assay (Promega, Fitchburg, WI, USA) and normalized to the protein content. Staurosporine (STS; Sigma-Aldrich) was used at 2.5 mM for 4 h (NALM-16 cells) or 24 h (REH cells), unless otherwise specified. The pancaspase inhibitor Q-VD-OPh (MP Biomedicals, Solon, OH, USA) was used at 10 mM. Etoposide (Hexal AG, Holzkirchen, Germany) was added to the cultures at 2.5 mM for 72 h. Human recombinant SuperKiller TRAIL (Enzo Life Sciences, Farmingdale, NY, USA) was used at 50 ng/ml for 10 h (NALM-16 cells) or 24 h (REH cells). Cytarabine (ARA-cell; Cellpharm, Bad Vilbern, Germany) was added to the cultures at 1 mM for 48 h. Daunorubicin (Pfizer, New York, NY, USA) was used at 0.5 mM overnight (NALM-16 cells) or for 24 h (REH cells). BrdU (5-bromo-2'-deoxyuridine) incorporation was measured by flow cytometry using anti-BrdU antibody according to the manufacturer's protocol (BD Biosciences).
Xenotransplantation model NOD.Cg-Prkdc
scid IL2rg tmWjl /Sz (also termed NOD/SCID/IL2Rg null , abbreviated as NSG) mice were purchased from Jackson Laboratory (Bar Harbor, ME, USA) and maintained under pathogen-free conditions according to the German federal and state regulations. EVI-1-shRNA-or control-shRNAtransduced NALM-16 cells were intravenously injected (5 Â 10 6 cells each) into the tail vein of non-irradiated 8-to 12-week-old NSG mice. From week 4 onwards, PB mononuclear cells were taken every 2 weeks and analyzed for surface expression of leukemia-specific markers by flow cytometry to monitor engraftment and phenotype of NSG-derived blasts. If engraftment exceeded 60% in the PB or if animals showed signs of wasting, animals were killed. Splenocytes or BM cells were re-transplanted into successive mouse generations. For pathological analyses, different organs were fixed in 4% formalin and embedded in paraffin. Immunohistochemical analysis was performed as described, 35 using antibodies against terminal deoxynucleotidyl transferase (TdT; Dako), CD10 (Novocastra, Newcastle upon Tyne, UK), CD19 (Zytomed, Berlin, Germany), active caspase-3 (Cell Signaling Technology) and Ki-67 (Epitomics, Burlingame, CA, USA).
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Statistical analyses
For all experiments, mean values are presented and error bars represent the s.e. P-values are derived via the application of a two-tailed, unpaired Student's t-test or as specified in the text. Survival analysis by KaplanMeier method was performed using the log-rank test (Mantel-Cox).
RESULTS EVI-1 is expressed in malignant cells of lymphoid origin and may predict adverse clinical outcome in pediatric ALL EVI-1 mRNA expression was evaluated by qPCR in a cohort of ALL and CLL patients ( Figure 1a ) and lymphoid cell lines ( Figure 1a and Supplementary Table 2 ). As healthy BM cells were reported to only weakly express EVI-1, whereas cells of AML subsets show high EVI-1 expression, AML samples were used as controls for high expression, and the average C t value of five BM samples from healthy donors was used as calibrator as previously reported. 6, 7, 13, 15, 16, 36 EVI-1 expression was detected in most of the analyzed samples. In lymphoid cell lines, higher expression was found in ALL lines from B-cell origin, such as NALM-16 and REH, whereas the cell lines of T-cell origin Jurkat, SC-1 and CML-T1 revealed lower EVI-1 expression levels (Figure 1a and  Supplementary Table 2 ). To define high EVI-1 expression and explore its potential clinical significance, cutoff values of 10, 25, 50 and 100 (relative expression 2 À DDCt ) were analyzed as described. 6 In this former study, high EVI-1 expression that associates with poor prognosis in AML was defined as exceeding the cutoff 50. In pediatric ALL, EVI-1 expression was lower than in AML, with no samples exceeding the cutoff value of 50. However, we noted an association between high-risk disease and EVI-1 expression above a cutoff of 25 (3/5 high-risk versus 2/26 non-high-risk patients; P ¼ 0.02, Fisher's exact test). As reported in AML, lowering the threshold to cutoff 10 resulted in non-significant results. Clinical data of the risk status were available in 30 out of 32 studied pediatric ALL patients (Supplementary Table 3 ). Of note, no significant expression of MDS1/EVI-1, which was reported to antagonize EVI-1, 37 was found in 27 out of 33 analyzed pediatric ALL samples using the same method (data not shown).
Inhibition of EVI-1 expression reduces cell growth and enhances basal apoptosis EVI-1 protein expression was confirmed by immunoblot analysis showing expression of EVI-1 (Evi-1a), and the isoforms MDS1/EVI-1 (Evi-1c), and truncated EVI-1 (Evi-1b; Supplementary Figure 1A) . 10 To explore the functional role of EVI-1 in ALL, we stably suppressed EVI-1 in two pre-B-ALL cell lines showing highest basal EVI-1 expression (NALM-16 and REH). We used two different EVI-1 inhibitory and two control shRNAs delivered by lentiviral vectors. Both EVI-1 shRNA constructs efficiently downregulated EVI-1 mRNA and protein expression, whereas expression was not altered by the control virus (Supplementary Figure 1) .
As compared with cells transduced with the control lentivirus, NALM-16 and REH EVI-1 knockdown cells showed significantly lower growth rates in vitro (Figure 2a ), which could be caused by decreased proliferation or enhanced apoptosis. Analysis of cell cycle progression revealed no cell cycle changes between cells expressing the control or EVI-1-specific shRNA (Figure 2b) . Consistently, no significant proliferation defect was detected by BrdU incorporation in EVI-1 knockdown versus control cells (Figure 2c ). However, both NALM-16 and REH EVI-1 knockdown cells revealed an elevated rate of spontaneous apoptosis, as shown by an increased fraction of sub-G1 cells and increased caspase-3/7 activity (Figure 2d ).
EVI-1 inhibition increases sensitivity to death receptor and mitochondrial death pathways To further explore the mechanisms underlying the phenotype of EVI-1 knockdown cells, we analyzed their response to several apoptosis-inducing agents. The protein kinase inhibitor STS, an inducer of the mitochondrial death pathway, dose-dependently induced apoptosis in both EVI-1 knockdown and control NALM-16 cells (Figure 3a and b, Supplementary Figure 2C ). STS-induced apoptosis was more pronounced in NALM-16 and REH EVI-1 knockdown cells than in corresponding control cells (Figure 3a and Supplementary Figures 2C and 3A) . The enhanced apoptosis sensitivity was not only detected by measurement of hypodiploid DNA, but also by increased caspase-3/7 activity, elevated caspase-3 processing and PARP cleavage (Figure 3b (a) EVI-1 expression is detectable at various levels in primary samples collected from BM and PB of patients with ALL and AML, as well as in a subfraction of PB samples from CLL patients (pediatric c-ALL, n ¼ 23; pediatric T-ALL, n ¼ 10; adult ALL, n ¼ 3; adult CLL, n ¼ 18; adult AML, n ¼ 21; healthy BM, n ¼ 5; lymphatic cell lines, n ¼ 6). Shown are relative gene expression levels as measured by real-time PCR relative to the mean EVI-1 expression in the five BM samples from healthy volunteers, which were used as calibrator (set as 1) as described. 6 Data was normalized to the internal control PBGD. (b) Correlation of EVI-1 expression with clinical risk profile in pediatric ALL patients. High EVI-1 expression was defined using a cutoff value of 25 (relative expression 2 À DDCt ), as reported. 6 Relative EVI-1 expression is significantly higher in the high-risk patient group (n ¼ 5) compared with the responsive patient group (n ¼ 26; Fisher's exact test, P ¼ 0.02). Figures 2D and 3B ). Cytarabine-induced apoptosis was also more pronounced in EVI-1 knockdown as compared with control NALM-16 cells (Figure 3c and Supplementary Figure 2D ) or REH cells (Supplementary Figure 3B) . Conversely, we generated NALM-16 cells overexpressing murine EVI-1 and corresponding control cells by transduction with lentiviruses carrying green fluorescent protein as a marker (Supplementary Figure 4) . 33 EVI-1 overexpression protected NALM-16 cells from apoptosis induced by STS, TRAIL and daunorubicin (Figure 4a) . Notably, the enhanced apoptosis sensitivity of EVI-1 knockdown NALM-16 cells could be rescued by concomitant treatment with lentiviruses carrying the murine EVI-1 overexpression construct (Figure 4b) , reinforcing that the observed phenotype is EVI-1-specific and not due to off-target effects.
As EVI-1 is a transcription factor, we investigated whether EVI-1 modulates apoptosis sensitivity by influencing the expression of various apoptosis-relevant genes by real-time PCR. We further included the cyclin-dependent kinase inhibitor p21 in the expression analysis. In line with the cell cycle analysis, EVI-1 knockdown and control NALM-16 and REH cells did not differ in p21 expression (Figure 5a and Supplementary Figure 3E) . In contrast, in both NALM-16 and REH cells, EVI-1 knockdown was associated with enhanced mRNA expression of the proapoptotic genes BAX and BAK, as well as of PUMA and NOXA, and with suppression of the anti-apoptotic genes BCL-2, BCL-x and XIAP (Figure 5a and Supplementary Figures 2G and 3E ). 38 Matching these results, EVI-1 overexpression yielded opposite effects enhancing the expression of BCL-x and decreasing expression of PUMA (Figure 5b) .
To further examine the role of EVI-1 in apoptosis, we analyzed the effects of TRAIL, which also resulted in a stronger apoptosis induction in EVI-1 knockdown as compared with control NALM-16 and REH cells (Figure 3c and Supplementary Figures 2E and 3C ). Figures 2F, 3D and 5B), whereas no changes were noted in TRAIL-R2 (data not shown). In NALM-16 cells, altered TRAIL-R1 expression was confirmed by flow cytometric analysis of mean fluorescence intensity and also documented on the mRNA level (Supplementary Figures 5A-C) . Conversely, NALM-16 cells overexpressing EVI-1 showed a lower percentage of TRAIL-R1-expressing cells (Supplementary Figure 5D) . However, siRNA treatment against TRAIL-R1 did not protect against TRAIL-induced apoptosis in NALM-16 cells (Supplementary Figures 5E and F) , even though it effectively inhibited TRAIL-R1 expression. Concomitant treatment of cells with a siRNA targeting TRAIL-R2 also did not confer protection against apoptosis, which however might be due to the low efficacy of the TRAIL-R2 knockdown. Together, these data suggest that at least in our cell systems TRAIL sensitivity is not primarily regulated by death receptor expression but rather by receptor downstream events, which is in line with previous reports in other types of cells.
EVI-1 knockdown was associated with an enhanced percentage of cells displaying surface expression of TRAIL-R1 (Supplementary
39-41
EVI-1 knockdown ALL cells exhibit severely impaired leukemic engraftment upon transplantation in a NSG mouse model To explore the relevance of EVI-1 in ALL in vivo, we performed xenotransplantation experiments of EVI-1 knockdown and control NALM-16 cells in immuno-permissive NSG mice. 42 As assayed by the expression of human CD45 and cell-type-specific antigens (Supplementary Table 5 ), low levels of EVI-1 knockdown cells were detectable in PB of xenotransplanted mice, whereas control cells revealed a robust engraftment. At all points in time, analyses performed on human CD45 (Figures 6a and b) and cell-typespecific antigens, such as CD19 and CD34, (Supplementary Table 5 ) yielded similar results (data not shown). To avoid gender-related bias in engraftment capacity, gender-matched mice were used for the analyses. 43, 44 In both male and female (Figures 6a and b) . Analyses of mice killed at week 7 after transplantation revealed pronounced infiltration of EVI-1-expressing NALM-16 cells in liver, spleen, kidney and other organs, as demonstrated by numbers of CD45 þ cells (Figure 6b ), hematoxylin and eosin, TdT, CD19 and CD10 staining (Figures 7a  and b, and Supplementary Figures 6A-D) . In contrast, organ infiltration was dramatically reduced in mice transplanted with EVI-1 knockdown cells, suggesting that EVI-1 is an important regulator of the leukemogenic properties in vivo (Figures 6b and  7c) . Similar results were obtained in secondary transplantations using pooled BM-derived cells (Figure 6c) . Importantly, gene expression analysis showed that the EVI-1 knockdown persisted in cells subjected to secondary transplantation (Supplementary Figure 6E) . Underscoring these results, the Kaplan-Meier analysis indicated an overall survival benefit for animals transplanted with EVI-1 shRNA-expressing cells as compared with those transplanted with NALM-16 cells expressing control shRNA (Figure 7d , P ¼ 0.003). Table 4) , and for caspase-3/7 activity (b). For the titration shown in a, percentages of sub-G1 cells were measured after 24 h of incubation with staurosporine. (c) Etoposide, daunorubicin, cytarabine and TRAIL induce higher percentages of sub-G1 apoptotic cells in EVI-1 knockdown as compared with control cells. Apoptosis was determined by PI staining of sub-G1 cells. Shown are values for specific apoptosis for each condition, calculated as the percentage of sub-G1 cells resulting after treatment with the individual agent minus the percentage of sub-G1 cells induced by treatment with the corresponding control vehicle. Shown are mean data±s.e. from three or more biological replicates, each performed in triplicates, with the exception of the titration experiment in a, where data from one representative experiment performed in technical triplicates are shown. In the immunoblot, lanes between bands were cut out for better visualization.
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Supporting our in vitro data, increased levels of active caspase-3 were detected in spleen sections of mice transplanted with knockdown EVI-1 cells as compared with control cells, whereas no difference was seen in the expression of the proliferation marker Ki-67 (Figure 7e) . Suppression of EVI-1 did not change surface antigen expression (CD19, CD10, CD34, CD33, CD20 and CD22) of in vitro cultured cells (Supplementary Table 5) , and histopathological analyses of the engrafted mice demonstrated that the phenotype of the leukemic cells (CD10, CD19, and especially TdT, a marker of early lymphocyte differentiation) was retained in NSG-derived specimens of the transferred NALM-16 cells (Supplementary Figure 6 and data not shown).
DISCUSSION
Since its identification in a retroviral integration site in myeloid leukemia, EVI-1 has been intensely studied for its role in the regulation of myeloid malignancies. 2, 3 In AML, EVI-1 overexpression can be due to recurrent rearrangements of the EVI-1 locus on chromosome band 3q26 or found in the absence of cytogenetically detectable rearrangements. AML patients displaying EVI-1 overexpression show similar clinical characteristics and a poor prognosis. 11, 6, 9, 45 Positive correlations have been reported between EVI-1 overexpression and the occurrence of mixed lineage leukemia rearrangements 9 and functional interactions between EVI-1 and mixed lineage leukemia oncoproteins suggested in AML. 13 Interestingly, Arai et al. 46 demonstrated transcriptional activation of EVI-1 by mixed lineage leukemia in HSCs but not in committed myeloid progenitor cells. 46 In contrast to the extensive knowledge on EVI-1 in myeloid malignancies, its role in cells of lymphoid origin remains largely undefined. PCR analyses could not detect EVI-1 expression in a limited number of T-cell leukemias. 26 However, EVI-1 rearrangement has been documented in a T-cell non-Hodgkin lymphoma patient carrying a t(3;9)(q26;p23) translocation, 25 and our retrospective analysis of microarray data retrieved from the Oncomine database identified EVI-1 expression in ALL. [27] [28] [29] Supporting the notion that EVI-1 has a role in lymphoblastic leukemia, EVI-1 was identified in a retroviral insertion site of a B-cell acute leukemia in a mouse model. 33, 47 In this report, we demonstrate that EVI-1 is expressed and has important roles in human lymphoid neoplasia.
High EVI-1 expression levels were more frequent in acute than in chronic lymphatic leukemia and more prominent in B-than T-cell-derived malignancies. Overall, EVI-1 levels in ALL appear lower than in AML, which may be due to cell-type-specific aspects. 6 However, in our pilot study performed on 33 pediatric ALL samples, 2 out of 5 patients initially showing high EVI-1 expression 6 died within 3 years and 1 patient underwent allogeneic transplantation because of high-risk disease.
During the last years, xenotransplantation in NOD/SCID mice has been increasingly utilized as a tool to study ALL biology. 48, 49 The microenvironment of the recently described NSG mouse has been shown to sustain leukemogenic cell growth and selfrenewal throughout serial transplantations in a superior way when compared with the traditional NOD/SCID strain and, moreover, to maintain the molecular and phenotypic profile of the xenotransplanted ALL cells. 50 Consistently, enhanced disease aggressiveness in patients is associated with a faster engraftment of leukemic cells in both the NOD/SCID 51 and the NSG mouse model (Andre MC, personal communication). To analyze the functional role of EVI-1 expression in lymphoblastic leukemia, we performed lentiviral knockdown of EVI-1 in two B-lymphoblastic cell lines, NALM-16 and REH, and used xenotransplantation into NSG mice as a surrogate assay to study the modulating effect of EVI-1 on ALL aggressiveness in vivo. In accordance with the results obtained in vitro, which showed impaired growth and enhanced spontaneous apoptosis in EVI-1 knockdown versus control cells, EVI-1 inhibition strongly reduced leukemic engraftment and prolonged the survival of xenotransplanted mice (P ¼ 0.003), suggesting an important role of EVI-1 during in vivo leukemogenesis from ALL cells.
As enhanced basal apoptosis but no other overt effects on cell cycle progression, proliferation or differentiation were detected in ALL cells upon EVI-1 knockdown, we further explored the role of EVI-1 during apoptosis induction. Indeed, treatment with various agents activating the intrinsic or extrinsic apoptosis pathway led to a higher apoptosis rate in EVI-1 knockdown as compared with control cells. It is thus conceivable that the increased sensitivity to apoptosis might contribute to the striking impairment of leukemic repopulation of EVI-1 knockdown cells in vivo. This correlation is supported by the elevated levels of active caspase-3 in organ sections of mice transplanted with EVI-1 knockdown cells. Suppression of EVI-1 likely did not affect the differentiation status Our data in ALL cells are consistent with findings in mouse HSCs isolated from EVI-1-deficient mice where enhanced apoptosis was seen in isolated hematopoietic progenitors. 13 However, in contrast to our findings in ALL cells, BM-derived HSCs from EVI-1-deficient mice revealed a significant decrease in proliferative capacity, 13 which has been linked to reduced levels of Gata2.
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In hematopoietic cells, EVI-1 was furthermore shown to protect from UV-irradiation-induced cell death by inhibiting c-Jun N-terminal kinase. 52 In rat intestinal epithelial cells, EVI-1 was shown to inhibit apoptosis by a process involving phosphoinositide-3-kinase and its downstream effector AKT. 53 Yoshimi et al. 54 recently demonstrated that EVI-1 inhibits apoptosis via PTEN/AKT/mTOR signaling and interactions with polycomb proteins in murine BM cells. In contrast, in ovarian cancer cells, downregulation of EVI-1 had no effect on apoptosis, underscoring that EVI-1-mediated effects are highly cell-type-specific. 55 Here we show that in ALL cells EVI-1 knockdown was associated with enhanced mRNA expression of the pro-apoptotic Bcl-2 proteins BAX, BAK, PUMA and NOXA. The multidomain proteins BAX and BAK, as well as the BH3-only proteins PUMA and NOXA, are central mediators of the intrinsic apoptosis pathway. 56 Upregulation of these pro-apoptotic mediators therefore most likely contributed to the enhanced apoptosis induction by etoposide, daunorubicine, cytarabine and STS upon EVI-1 knockdown. Furthermore, EVI-1 knockdown reduced expression of the anti-apoptotic genes BCL-2 and BCL-x that counteract proapoptotic Bcl-2 proteins, thereby further enhancing apoptosis sensitivity. The reduced expression of XIAP, a caspase-inhibitory protein, but also of BCL-x, which has been implicated as an EVI-1 target gene in colon carcinoma cells, might contribute to EVI-1-mediated apoptosis modulation and also explain the enhanced apoptosis sensitivity in response to death ligands. 57 We also observed a consistent upregulation of TRAIL-R1 in response to EVI-1 modulation. However, effects of EVI-1 on TRAIL-R1 presumably have a minor role, as suppression of TRAIL-R1 did not protect from TRAIL-mediated apoptosis. Our data rather support the notion that in lymphoblastic leukemia cells, EVI-1 regulates events downstream of death receptors, such as expression of BCL-x and potentially other apoptosis-related genes.
Taken together, our data demonstrate an unsuspected role of EVI-1 in ALL. We show that high EVI-1 expression might be associated with disease aggressiveness in pediatric ALL, although future studies on larger cohorts of patients are needed to explore EVI-1 as a risk factor in ALL. Furthermore, we demonstrate that EVI-1 knockdown suppresses leukemogenesis and prolongs survival in a xenotransplant mouse model. Selective EVI-1 inhibitors applicable for in vivo therapy still need to be developed. Interestingly, arsenic trioxide has been reported to induce degradation of EVI-1 58 and, in combination with thalidomide, to induce hematological remission in MDS patients with high EVI-1 expression. 59 Moreover, EVI-1 interacts with histone deacetylases and methyltransferases for transcriptional regulation, [21] [22] [23] [24] and drugs that impact on epigenetic modifications might inhibit EVI-1-mediated adverse effects. Recently, a pyrrole-imidazole polyamide was developed, which specifically blocks EVI-1 binding to DNA. 60 As EVI-1 inhibition sensitizes for apoptosis induction by TRAIL and other drugs, the combined treatment with apoptosis-targeting and EVI-1-modulating drugs might enhance the treatment EVI-1 regulates lymphoblastic leukemia M Konantz et al
